Literature DB >> 32194688

Prognostic value of key genes of the JAK-STAT signaling pathway in patients with cutaneous melanoma.

Fuqiang Pan1, Qiaoqi Wang1, Sizhu Li2, Rui Huang3, Xiangkun Wang4, Xiwen Liao4, Haiyan Mo1, Liming Zhang1, Xiang Zhou1.   

Abstract

The Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway is involved in cell immunity, division and death, as well as in tumor formation. The expression of key genes in the JAK-STAT signaling pathway in different types of cancer serves different roles. However, few reports are available on the prognostic value of the genes of the JAK-STAT signaling pathway in skin cutaneous melanoma (SKCM). The potential prognostic value of gene expression in the JAK-STAT signaling pathway in patients with SKCM was analyzed in the present study using data obtained from The Cancer Genome Atlas. To predict the potential functions and mechanisms of these genes in SKCM, gene set enrichment analysis (GSEA) and bioinformatics analysis were performed. A nomogram model including gene expression level and high risk factors was used to predict the risk level of prognostic. High expression levels of STAT1, STAT3, STAT4 and STAT5B, and low expression levels of STAT6 were associated with favorable prognosis [adjusted P<0.001; hazard ratio (HR), 0.595; 95% confidence interval (CI), 0.455-0.778; adjusted P=0.018; HR, 0.725; 95% CI, 0.555-0.947; adjusted P<0.001; HR, 0.590; 95% CI, 0.450-0.773; adjusted P=0.007; HR, 0.690; 95% CI, 0.526-0.940; and adjusted P=0.026; HR, 0.737, 95% CI, 0.563-0.964, respectively]. GSEA results demonstrated that these genes were involved in cell differentiation, invasion, adhesion, migration, cycle, colony formation and mitogen-activated protein kinase signaling. The combination of genes with favorable prognosis had a better effect on the overall survival (univariate survival analysis, P<0.05). The results of the present study suggest that STAT1, STAT3, STAT4, STAT5B and STAT6 gene expression may be used as a potential prognostic biomarker of SKCM, and the combined outcomes may exhibit a stronger interaction and higher survival time for SKCM. Copyright: © Pan et al.

Entities:  

Keywords:  Janus kinase-signal transducer and activator of transcription signaling pathway; melanoma; prognosis

Year:  2020        PMID: 32194688      PMCID: PMC7039088          DOI: 10.3892/ol.2020.11287

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  69 in total

1.  MicroRNA-214 inhibits the proliferation and invasion of lung carcinoma cells by targeting JAK1.

Authors:  Xiaofeng Chen; Jiangyuan Du; Rui Jiang; Ling Li
Journal:  Am J Transl Res       Date:  2018-04-15       Impact factor: 4.060

2.  Long non-coding RNA HOTAIR and STAT3 synergistically regulate the cervical cancer cell migration and invasion.

Authors:  Yan Zhang; Xiaoling Cheng; Hua Liang; Zhenzhen Jin
Journal:  Chem Biol Interact       Date:  2018-03-20       Impact factor: 5.192

Review 3.  Janus kinases in immune cell signaling.

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

Review 4.  Novel biomarkers in malignant melanoma.

Authors:  Anja K Bosserhoff
Journal:  Clin Chim Acta       Date:  2006-02-09       Impact factor: 3.786

5.  The Molecular Signatures Database (MSigDB) hallmark gene set collection.

Authors:  Arthur Liberzon; Chet Birger; Helga Thorvaldsdóttir; Mahmoud Ghandi; Jill P Mesirov; Pablo Tamayo
Journal:  Cell Syst       Date:  2015-12-23       Impact factor: 10.304

6.  STAT-1 expression is regulated by IGFBP-3 in malignant glioma cells and is a strong predictor of poor survival in patients with glioblastoma.

Authors:  Balaram Thota; Arivazhagan Arimappamagan; Thennarasu Kandavel; Arun H Shastry; Paritosh Pandey; Bangalore Ashwathnarayanarao Chandramouli; Alangar Sathyaranjandas Hegde; Paturu Kondaiah; Vani Santosh
Journal:  J Neurosurg       Date:  2014-05-30       Impact factor: 5.115

Review 7.  A Progressive Review of V600E-B-RAF-Dependent Melanoma and Drugs Inhibiting It.

Authors:  Mohammad Ashrafuddin Khan; Mohammed I El-Gamal; Chang-Hyun Oh
Journal:  Mini Rev Med Chem       Date:  2017       Impact factor: 3.862

8.  Dysregulated STAT1-SOCS1 control of JAK2 promotes mammary luminal progenitor cell survival and drives ERα(+) tumorigenesis.

Authors:  S R Chan; C G Rickert; W Vermi; K C F Sheehan; C Arthur; J A Allen; J M White; J Archambault; S Lonardi; T M McDevitt; D Bhattacharya; M V Lorenzi; D C Allred; R D Schreiber
Journal:  Cell Death Differ       Date:  2013-09-13       Impact factor: 15.828

9.  Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.

Authors:  Hiroki Sumiyoshi; Akira Matsushita; Yoshiharu Nakamura; Yoko Matsuda; Toshiyuki Ishiwata; Zenya Naito; Eiji Uchida
Journal:  Oncol Rep       Date:  2016-04-01       Impact factor: 3.906

10.  STAT3 expression is associated with poor survival in non-elderly adult patients with newly diagnosed multiple myeloma.

Authors:  Sung-Hoon Jung; Seo-Yeon Ahn; Hyun-Woo Choi; Myung-Geun Shin; Seung-Shin Lee; Deok-Hwan Yang; Jae-Sook Ahn; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Blood Res       Date:  2017-12-26
View more
  2 in total

1.  3, 3'- (3, 5-DCPBC) Down-Regulates Multiple Phosphokinase Dependent Signal Transduction Pathways in Malignant Melanoma Cells through Specific Diminution of EGFRY1086 Phosphorylation.

Authors:  Abhijit Basu; M Iqbal Choudhary; Karin Scharffetter-Kochanek
Journal:  Molecules       Date:  2022-02-09       Impact factor: 4.411

2.  Association of JAK/STAT genetic variants with cutaneous melanoma.

Authors:  Gabriela Vilas Bôas Gomez; Gustavo Jacob Lourenço; Lummy Maria Oliveira Monteiro; Rafael Silva Rocha; Kimberly Anne McGrail Fernández; Juan Angel Recio; Caroline Torricelli; Lilian Oliveira Coser; Alexandre Leite Rodrigues Oliveira; Juliana Carron; Aparecida Machado Moraes; Carmen Silvia Passos Lima
Journal:  Front Oncol       Date:  2022-08-02       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.